Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RaSTA: Raltegravir Switch for Toxicity or Adverse Events
NCT00958100Phase 2Completed
- Sponsor
- Università Cattolica del Sacro Cuore
- Start
- Aug 2009
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by Università Cattolica del Sacro Cuore. Started Aug 2009; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00958100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00958100.